GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (MEX:BLUE) » Definitions » Institutional Ownership

bluebird bio (MEX:BLUE) Institutional Ownership : 20.92% (As of Dec. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is bluebird bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, bluebird bio's institutional ownership is 20.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, bluebird bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, bluebird bio's Float Percentage Of Total Shares Outstanding is 92.33%.


bluebird bio Institutional Ownership Historical Data

The historical data trend for bluebird bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Institutional Ownership Chart

bluebird bio Historical Data

The historical data trend for bluebird bio can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 32.65 31.46 28.77 28.06 26.24 27.45 23.54 22.10 20.87 20.92

bluebird bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


bluebird bio Business Description

Traded in Other Exchanges
Address
455 Grand Union Boulevard, Somerville, MA, USA, 02145
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.